US 11254940
Inhibition of MAP4K4 through RNAi
granted A61PA61P17/06A61P27/02
Quick answer
US patent 11254940 (Inhibition of MAP4K4 through RNAi) held by Phio Pharmaceuticals Corp. expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Phio Pharmaceuticals Corp.
- Grant date
- Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61P, A61P17/06, A61P27/02, A61P29/00, A61P3/00